DSM421 is a dihydroorotate Dehydrogenase Inhibitor (DHODH) with Improved Drug-like Properties for Treatment and Prevention of Malaria. SM421 showed equal activity against both P. falciparum and P. vivax field isolates. DSM421 has the potential to be developed as a single-dose cure or once-weekly chemopreventative for both P. falciparum and P. vivax malaria, leading to its advancement as a preclinical development candidate.
Uses
DSM-421 is an orally active Dihydroorotate dehydrogenase inhibitor. DSM-421 has antiplasmodium activity[1].
in vivo
DSM-421 (0.1-30 mg/kg orally for 4 consecutive days) has strong antimalarial activity in a SCID mouse model of Plasmodium falciparum [1].
References
[1] Phillips MA, et al. A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria. ACS Infect Dis. 2016 Dec 9;2(12):945-957. DOI:10.1021/acsinfecdis.6b00144
